Abstracts tagged "Measurement Instrument"

Abstract Number: 2609 • ACR Convergence 2025
Evaluation of the Performance of Candidate Enthesitis Ultrasound Scoring Systems for Psoriatic Arthritis Diagnosis – DUET Study
Nam Nguyen¹, Mu Yang², Sibel Aydin³, Gurjit Kaeley⁴, Richard Cook² and Lihi Eder¹, ¹University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, Canada, ³Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Psoriatic arthritis (PsA) is often diagnosed late, leading to worse outcomes. Enthesitis is a key feature that can aid in early detection, but its…
Abstract Number: 0605 • ACR Convergence 2025
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
Anubhav Singh¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Zoila Rodriguez-Bellido⁴, Cesar Pastor-Asurza⁵, Risto Perich-Campos⁶, Manuel Ugarte-Gil⁷ and Graciela Alarcón⁸, ¹Baptist hospital of southeast Texas, Beaumont, TX, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷Universidad Cientifica del Sur, Lima, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) was developed to ascertain frailty in systemic lupus erythematosus (SLE) patients. The aim of this…
Abstract Number: 2554 • ACR Convergence 2025
Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
Didem Saygin¹, Elizabeth Neal², Edward O'Bryan³, Alisha Smith, PharmD³, Leslie Myers³ and Timothy Walton³, ¹Rush University Medical Center, Chicago, IL, ²CSI Pharmacy, Nash, TX, ³CSI Pharmacy, Nash
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are autoimmune diseases typically characterized by muscle weakness. Intravenous Immunoglobulin (IVIg) is an effective immunomodulatory therapy in patients with refractory…
Abstract Number: 0791 • ACR Convergence 2025
Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine
Leila Khalili¹, Cynthia Aranow², Mimi Kim³, Diane Kamen⁴, Cristina Arriens⁵, Alberto Nordmann-Gomes⁶, Maya Souvignier⁶, Wei Tang⁷, Stephen Suh⁸, Maria Dall'Era⁹, Meghan mackay¹⁰ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Medical University of South Carolina, Johns Island, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Columbia University Irving Medical Center, New York, NY, ⁷Westchester Medical Center, Valhalla, NY, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Division of Rheumatology, University of California, San Francisco, CA, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We previously described the top-line results of our study and the high correlations between virtual SLE disease activity measures (DAM) and those obtained during…
Abstract Number: 2542 • ACR Convergence 2025
A Rule Based NLP Pipeline for Glucocorticoid exposure
Simran Nimal¹, Megan Sullivan¹, Christopher Conyers², Joseph Rosen¹, Christopher Grilli¹, Kenneth Warrington³ and Victor E Ortega¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Scottsdale-⁸⁵²⁵⁹, AZ, ³Mayo Clinic, ROCHESTER, MN
Background/Purpose: Glucocorticoids (GCs) are essential for managing giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), but prolonged use poses risk due to cumulative dosing and…
Abstract Number: 0777 • ACR Convergence 2025
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
Kevin Byram¹, Herman Mann², Danielle Hammond³, Sinisa Savic⁴, Yohei Kirino⁵, Carmelo Gurnari⁶, Mael Heiblig⁷, Thibault Comont⁸, Arsène Mekinian⁹, Mrinal Patnaik¹⁰, Lachelle D. Weeks¹¹, Gary Ho¹², Onima Chowdhury¹³, Adam Al-Hakim¹⁴, Scott Goldberg¹⁵, Marcela ferrada¹⁶, Sophie georgin-Lavialle¹⁷, Peter Grayson¹⁸, Emma Groarke¹⁹, Bhavisha Patel²⁰, Megan Sullivan²¹, Sarah A. Buckley²², Bryan G. harder²², Sandra Goble²², Matthew Koster¹⁰ and David Beck²³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Institute of Rheumatology, Praha ², Czech Republic, ³The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁷Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁸Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ⁹Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Dana Farber Cancer Institute, Boston, MA, ¹²New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ¹³Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ¹⁴University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine,, Leeds, United Kingdom, ¹⁵New York University Grossman School of Medicine, Brooklyn, NY, ¹⁶University of Maryland, Bethesda, MD, ¹⁷Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹⁹National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ²⁰National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ²¹Mayo Clinic Arizona, Scottsdale, AZ, ²²Sobi Inc., Waltham, MA, ²³Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY
Background/Purpose: VEXAS syndrome is a recently described severe disease characterized by a complex overlap of inflammatory and hematologic features. Due to the severity and refractory…
Abstract Number: 2483 • ACR Convergence 2025
Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
Gulsen Ozen¹, Lan Yu², Maureen Lauffoon², John Pauling³ and Robyn Domsic², ¹University of Iowa Carver College of Medicine, Coralville, IA, ²University of Pittsburgh, Pittsburgh, PA, ³North Bristol NHS Trust, Bristol, United Kingdom
Background/Purpose: Raynaud’s phenomenon (RP) is the most common manifestation of systemic sclerosis (SSc) leading to substantial pain and impaired hand function. Establishing treatment efficacy for…
Abstract Number: 0449 • ACR Convergence 2025
Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Joel Kremer¹, Kevin Kane², George Reed³ and Michael Weinblatt⁴, ¹The Corrona Research Foundation, Delray Beach, FL, ²U of Mass Medical School, Worcester, MA, MA, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Low disease activity has been identified as a treatment goal for the treatment of RA. A singlecenter RA registry (BRASS) reported a difference in…
Abstract Number: 0546 • ACR Convergence 2024
Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice
Nehad Soloman¹, Jawad Bilal² and John Tesser³, ¹Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, ²Arizona Arthritis & Rheumatology Associates, PC, Tucson, AZ, ³Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting 1.4% of the US adult population. The leading clinical symptom of axSpA is chronic inflammatory…
Abstract Number: 1155 • ACR Convergence 2024
Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³ and elvira Diez álvarez⁴, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, Leon
Background/Purpose: Idiopathic inflammatory myopathies (IIM) carry an elevated risk of cancer incidence. Recently published International Guidelines for IIM-associated cancer screening from the Myositis Assessment and…
Abstract Number: 1182 • ACR Convergence 2024
Assessing Male Pelvic Floor Contractions Using a Novel External Pressure Device and Ultrasound
Benedetto Giardulli¹, Mirko Job¹, Filippo Recenti¹, Gaia Leuzzi¹, Alessandro Muda², Ottavia Buccarella¹ and Marco Testa¹, ¹University of Genova, Savona, Italy, ²Lavagna Hospital - Radiology Dept., Genova, Italy
Background/Purpose: Men with rheumatic and musculoskeletal diseases (RMD) often experience sexual dysfunctions such as pelvic floor pain and erectile dysfunctions, which affect their sexual well-being.…
Abstract Number: 1351 • ACR Convergence 2024
Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements
Woo-Joong KIM¹, Chanseok PARK², Seungmo KOO², Jae-Young CHEONG² and Jiho KIM², ¹Chung-Ang University Hospital, Seoul, Korea, Seoul, Republic of Korea, ²Hongik University, Seoul, Korea, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires regular monitoring to prevent joint damage and systemic complications. However, the shortage of trained…
Abstract Number: 1538 • ACR Convergence 2024
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, ¹Rush University, Chicago, IL, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Rheum101, Rockville, MD
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
Abstract Number: 1689 • ACR Convergence 2024
Pulmonary Function Test Reference Equations May Drive Inequitable Classification of Restrictive Lung Disease Severity in Systemic Sclerosis
Kamini Kuchinad¹, Rachel Wallwork², Matthew Lammi³, Christopher Mecoli¹, Julie Paik¹, Fredrick Wigley⁴, Robert Wise¹, Laura Hummers⁵, Ami Shah⁶ and Ji Soo Kim¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Towson, MD, ³Johns Hopkins University Division of Pulmonary and Critical Care Medicine, Baltimore, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁶Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Black individuals with systemic sclerosis (SSc) have an increased frequency and severity of interstitial lung disease (ILD) as compared to their White counterparts. Pulmonary…
Abstract Number: 1968 • ACR Convergence 2024
Development and Validation of an Arthritis-Detection Algorithm Using Thermal Imaging in Adults and Children
Thomason Jenna¹, Sullivan Erin², Rajdeep Pooni³, Liau Adriel⁴, Sadie Van den Bogaerde⁵, Audrey Luey⁶, Iris Hamilton⁷, Sriya Paluvayi⁶, Megan Tran¹, Janeth Robles-Navarro¹, Ian Muse⁸, Ava Klein⁴, Tzielan Lee⁹, Grant Hughes⁵, Alison Bays⁵, Elizabeth Ferucci¹⁰, Debosmita Biswas¹¹, Savannah Patridge¹¹ and Yongdong (Dan) Zhao¹², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²Biostatistics, Epidemiology, and Analytics in Research (BEAR) Core, Seattle Children’s Research Institute, Seattle, WA, ³Stanford University, Palo Alto, CA, ⁴Seattle Children’s Research Institute, University of Washington, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, University of Washington, Seattle, WA, ⁷Seattle Children's Hospital, Seattle, ⁸Seattle Children's Research institute, Seattle, WA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Alaska Native Tribal Health Consortium, Anchorage, AK, ¹¹University of Washington, Department of Radiology, Seattle, WA, ¹²University of Washington, Redmond, WA
Background/Purpose: The Thermal imaging-based Temperature After Within-limb Calibration (TAWiC) algorithm for the detection of arthritis in the knees has been validated in children by our…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].